Comprehensive Breast Cancer Website

OncologyONCOLOGY Vol 15 No 5
Volume 15
Issue 5

Breast Cancer On-Line (BCO) at is a multidisciplinary website based in the United Kingdom that may be useful to practicing oncologists, nurses, and scientists working in the field of oncology. The editor-in-chief is John Robertson,

Breast Cancer On-Line (BCO) at is a multidisciplinary website based in the United Kingdom that may be useful to practicingoncologists, nurses, and scientists working in the field of oncology. Theeditor-in-chief is John Robertson, professor of surgery at City Hospital, inNottingham, and the editorial board comprises an international team of prominentphysicians.

Supported by an educational grant from AstraZeneca, BCO iscomprehensive and regularly updated. Among its features are interactive modulesthat contain a number of excellent resources. For example, Journal Club offersrecent articles by both clinicians and scientists, accompanied by criticalreviews. Journal Watch is a monthly update of articles relevant to breast cancercare.

Expert Opinion invites readers to submit clinical cases forexpert comment and reader feedback as well. The Focus On department providestimely, concise, and referenced reviews of current topics (such as pain in thebreast cancer patient) and also invites reader feedback.

Educational Modules

The website’s educational modules include a multiple-chapterNurse Education section dedicated to nurses in cancer care and a fully archivedCase Studies section that allows readers to consider interesting clinical cases.These areas are informative and allow professionals to test their knowledge andreceive quick feedback. Further opportunities for self-assessment are providedin the Visual Library section, a unique array of radiologic and histopathologicimages based on various clinical themes.

Other useful features include a conference calendar and avariety of conference reports, which summarize the major findings presented athalf a dozen major oncology meetings. The report on the Miami Breast CancerConference, for example, contains "quick takes" of major pointsemphasized at the meeting. The Breast Cancer News section contains a year’sworth of highlights.

Links to Other Resources

A larger database can be accessed through the Informationsection. In fact, the reader has access to Medline, Grateful Med, PDQ, and ahost of cancer resources, including several cancer journals, some of whichcontain full text. Lastly, there are numerous links to online cancer sites, bothfor professionals and consumers, with quick access.

Related Videos
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Sara M. Tolaney, MD, MPH, an expert on breast cancer
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Ann H. Partridge, MD, MPH, talks about how fertility preservation can positively impact the psychosocial health in patients with breast cancer.
Daniel G. Stover, MD, describes how findings from the phase 3 NATALEE trial may support expanding the portion of patients who receive CDK 4/6 inhibitors as a treatment for hormone receptor–positive, HER2-negative breast cancer.
Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive,  HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.
Related Content